Some key questions in Epstein-Barr virus (EBV) biology center on whether naturally occurring sequence differences in the virus affect infection or EBV associated diseases. Understanding the pattern of EBV sequence variation is also important for possible development of EBV vaccines. At present EBV isolates worldwide can be grouped into Type 1 and Type 2, a classification based on the EBNA2 gene sequence. Type 1 EBV is the most prevalent worldwide but Type 2 is common in parts of Africa. Type 1 transforms human B cells into lymphoblastoid cell lines much more efficiently than Type 2 EBV. Molecular mechanisms that may account for this difference in cell transformation are now becoming clearer. Advances in sequencing technology will greatly increase the amount of whole EBV genome data for EBV isolated from different parts of the world. Study of regional variation of EBV strains independent of the Type 1/Type 2 classification and systematic investigation of the relationship between viral strains, infection and disease will become possible. The recent discovery that specific mutation of the EBV EBNA3B gene may be linked to development of diffuse large B cell lymphoma illustrates the importance that mutations in the virus genome may have in infection and human disease.
References
[1]
Rickinson, A.; Kieff, E. Epstein-Barr Virus. In Fields Virology, Fifth; Knipe, D., Howley, P., Eds.; Lippincott, Williams and Wilkins: Philadelphia, PA, USA, 2007; pp. 2655–2700.
[2]
Jenkins, P.J.; Farrell, P.J. Are particular Epstein-Barr virus strains linked to disease? Semin. Cancer Biol. 1996, 7, 209–215, doi:10.1006/scbi.1996.0028.
[3]
White, R.E.; Ramer, P.C.; Naresh, K.N.; Meixlsperger, S.; Pinaud, L.; Rooney, C.; Savoldo, B.; Coutinho, R.; Bodor, C.; Gribben, J.; et al. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J. Clin. Invest. 2012, 122, 1487–1502.
[4]
Cheung, A.; Kieff, E. Long internal direct repeat in Epstein-Barr virus DNA. J. Virol. 1982, 44, 286–294.
[5]
Dambaugh, T.R.; Kieff, E. Identification and nucleotide sequences of two similar tandem direct repeats in Epstein-Barr virus DNA. J. Virol. 1982, 44, 823–833.
[6]
Baer, R.; Bankier, A.T.; Biggin, M.D.; Deininger, P.L.; Farrell, P.J.; Gibson, T.J.; Hatfull, G.; Hudson, G.S.; Satchwell, S.C.; Seguin, C.; et al. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 1984, 310, 207–211.
[7]
Miller, G.; Shope, T.; Lisco, H.; Stitt, D.; Lipman, M. Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocyte. Proc. Natl. Acad. Sci. USA 1972, 69, 383–387.
[8]
Arrand, J.R.; Rymo, L.; Walsh, J.E.; Bjorck, E.; Lindahl, T.; Griffin, B.E. Molecular cloning of the complete Epstein-Barr virus genome as a set of overlapping restriction endonuclease fragments. Nucleic Acids Res. 1981, 9, 2999–3014.
[9]
Raab-Traub, N.; Dambaugh, T.; Kieff, E. DNA of Epstein-Barr virus VIII: B95-8, the previous prototype, is an unusual deletion derivative. Cell 1980, 22, 257–267, doi:10.1016/0092-8674(80)90173-7.
[10]
Parker, B.D.; Bankier, A.; Satchwell, S.; Barrell, B.; Farrell, P.J. Sequence and transcription of Raji Epstein-Barr virus DNA spanning the B95-8 deletion region. Virology 1990, 179, 339–346.
[11]
de Jesus, O.; Smith, P.R.; Spender, L.C.; Elgueta Karstegl, C.; Niller, H.H.; Huang, D.; Farrell, P.J. Updated Epstein-Barr virus (EBV) DNA sequence and analysis of a promoter for the BART (CST, BARF0) RNAs of EBV. J. Gen. Virol. 2003, 84, 1443–1450, doi:10.1099/vir.0.19054-0.
[12]
Fruscalzo, A.; Marsili, G.; Busiello, V.; Bertolini, L.; Frezza, D. DNA sequence heterogeneity within the Epstein-Barr virus family of repeats in the latent origin of replication. Gene 2001, 265, 165–173, doi:10.1016/S0378-1119(01)00345-6.
[13]
Kanda, T.; Shibata, S.; Saito, S.; Murata, T.; Isomura, H.; Yoshiyama, H.; Takada, K.; Tsurumi, T. Unexpected instability of family of repeats (FR), the critical cis-acting sequence required for EBV latent infection, in EBV-BAC systems. PLoS One 2011, 6, e27758.
[14]
Dolan, A.; Addison, C.; Gatherer, D.; Davison, A.J.; McGeoch, D.J. The genome of Epstein-Barr virus type 2 strain AG876. Virology 2006, 350, 164–170, doi:10.1016/j.virol.2006.01.015.
[15]
Zeng, M.S.; Li, D.J.; Liu, Q.L.; Song, L.B.; Li, M.Z.; Zhang, R.H.; Yu, X.J.; Wang, H.M.; Ernberg, I.; Zeng, Y.X. Genomic sequence analysis of Epstein-Barr virus strain GD1 from a nasopharyngeal carcinoma patient. J. Virol. 2005, 79, 15323–15330.
[16]
Liu, P.; Fang, X.; Feng, Z.; Guo, Y.M.; Peng, R.J.; Liu, T.; Huang, Z.; Feng, Y.; Sun, X.; Xiong, Z.; et al. Direct sequencing and characterization of a clinical isolate of Epstein-Barr virus from nasopharyngeal carcinoma tissue by using next-generation sequencing technology. J. Virol. 2011, 85, 11291–11299, doi:10.1128/JVI.00823-11.
[17]
Kwok, H.; Tong, A.H.; Lin, C.H.; Lok, S.; Farrell, P.J.; Kwong, D.L.; Chiang, A.K. Genomic sequencing and comparative analysis of epstein-barr virus genome isolated from primary nasopharyngeal carcinoma biopsy. PLoS One 2012, 7, e36939.
[18]
Dambaugh, T.; Hennessy, K.; Chamnankit, L.; Kieff, E. U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2. Proc. Natl. Acad. Sci. USA 1984, 81, 7632–7636, doi:10.1073/pnas.81.23.7632.
[19]
Adldinger, H.K.; Delius, H.; Freese, U.K.; Clarke, J.; Bornkamm, G.W. A putative transforming gene of Jijoye virus differs from that of Epstein-Barr virus prototypes. Virology 1985, 141, 221–234, doi:10.1016/0042-6822(85)90253-3.
[20]
Rowe, M.; Young, L.S.; Cadwallader, K.; Petti, L.; Kieff, E.; Rickinson, A.B. Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins. J. Virol. 1989, 63, 1031–1039.
[21]
Rickinson, A.B.; Young, L.S.; Rowe, M. Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J. Virol. 1987, 61, 1310–1317.
[22]
Midgley, R.S.; Blake, N.W.; Yao, Q.Y.; Croom-Carter, D.; Cheung, S.T.; Leung, S.F.; Chan, A.T.; Johnson, P.J.; Huang, D.; Rickinson, A.B.; et al. Novel intertypic recombinants of epstein-barr virus in the chinese population. J. Virol. 2000, 74, 1544–1548.
[23]
Yao, Q.Y.; Tierney, R.J.; Croom-Carter, D.; Cooper, G.M.; Ellis, C.J.; Rowe, M.; Rickinson, A.B. Isolation of intertypic recombinants of Epstein-Barr virus from T-cell-immunocompromised individuals. J. Virol. 1996, 70, 4895–4903.
[24]
Kim, S.M.; Kang, S.H.; Lee, W.K. Identification of two types of naturally-occurring intertypic recombinants of Epstein-Barr virus. Mol. Cells 2006, 21, 302–307.
[25]
McGeoch, D.J.; Gatherer, D. Lineage structures in the genome sequences of three Epstein-Barr virus strains. Virology 2007, 359, 1–5, doi:10.1016/j.virol.2006.10.009.
[26]
Schuster, V.; Ott, G.; Seidenspinner, S.; Kreth, H.W. Common Epstein-Barr virus (EBV) type-1 variant strains in both malignant and benign EBV-associated disorders. Blood 1996, 87, 1579–1585.
[27]
Suspene, R.; Aynaud, M.M.; Koch, S.; Pasdeloup, D.; Labetoulle, M.; Gaertner, B.; Vartanian, J.P.; Meyerhans, A.; Wain-Hobson, S. Genetic editing of herpes simplex virus 1 and Epstein-Barr herpesvirus genomes by human APOBEC3 cytidine deaminases in culture and in vivo. J. Virol. 2011, 85, 7594–7602, doi:10.1128/JVI.00290-11.
[28]
Burrows, J.M.; Bromham, L.; Woolfit, M.; Piganeau, G.; Tellam, J.; Connolly, G.; Webb, N.; Poulsen, L.; Cooper, L.; Burrows, S.R.; et al. Selection pressure-driven evolution of the Epstein-Barr virus-encoded oncogene LMP1 in virus isolates from Southeast Asia. J. Virol. 2004, 78, 7131–7137, doi:10.1128/JVI.78.13.7131-7137.2004.
[29]
Midgley, R.S.; Bell, A.I.; McGeoch, D.J.; Rickinson, A.B. Latent gene sequencing reveals familial relationships among Chinese Epstein-Barr virus strains and evidence for positive selection of A11 epitope changes. J. Virol. 2003, 77, 11517–11530, doi:10.1128/JVI.77.21.11517-11530.2003.
[30]
Midgley, R.S.; Bell, A.I.; Yao, Q.Y.; Croom-Carter, D.; Hislop, A.D.; Whitney, B.M.; Chan, A.T.; Johnson, P.J.; Rickinson, A.B. HLA-A11-restricted epitope polymorphism among Epstein-Barr virus strains in the highly HLA-A11-positive Chinese population: incidence and immunogenicity of variant epitope sequences. J. Virol. 2003, 77, 11507–11516.
[31]
Nagamine, M.; Kishibe, K.; Takahara, M.; Nagato, T.; Ishii, H.; Bandoh, N.; Ogino, T.; Harabuchi, Y. Selected amino acid change encoding Epstein-Barr virus-specific T cell epitope of the LMP2A gene in Japanese nasal NK/T cell lymphoma patients. Intervirology 2007, 50, 319–322, doi:10.1159/000106462.
[32]
Tang, Y.L.; Lu, J.H.; Cao, L.; Wu, M.H.; Peng, S.P.; Zhou, H.D.; Huang, C.; Yang, Y.X.; Zhou, Y.H.; Chen, Q.; et al. Genetic variations of EBV-LMP1 from nasopharyngeal carcinoma biopsies: potential loss of T cell epitopes. Braz. J. Med. Biol. Res. 2008, 41, 110–116.
[33]
Lin, J.C.; Cherng, J.M.; Lin, H.J.; Tsang, C.W.; Liu, Y.X.; Lee, S.P. Amino acid changes in functional domains of latent membrane protein 1 of Epstein-Barr virus in nasopharyngeal carcinoma of southern China and Taiwan: prevalence of an HLA A2-restricted 'epitope-loss variant'. J. Gen. Virol. 2004, 85, 2023–2034, doi:10.1099/vir.0.19696-0.
[34]
Lin, H.J.; Cherng, J.M.; Hung, M.S.; Sayion, Y.; Lin, J.C. Functional assays of HLA A2-restricted epitope variant of latent membrane protein 1 (LMP-1) of Epstein-Barr virus in nasopharyngeal carcinoma of Southern China and Taiwan. J. Biomed. Sci. 2005, 12, 925–936, doi:10.1007/s11373-005-9017-y.
[35]
Duraiswamy, J.; Burrows, J.M.; Bharadwaj, M.; Burrows, S.R.; Cooper, L.; Pimtanothai, N.; Khanna, R. Ex vivo analysis of T-cell responses to Epstein-Barr virus-encoded oncogene latent membrane protein 1 reveals highly conserved epitope sequences in virus isolates from diverse geographic regions. J. Virol. 2003, 77, 7401–7410, doi:10.1128/JVI.77.13.7401-7410.2003.
[36]
Kelly, G.; Bell, A.; Rickinson, A. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat. Med. 2002, 8, 1098–1104, doi:10.1038/nm758.
[37]
Kelly, G.L.; Long, H.M.; Stylianou, J.; Thomas, W.A.; Leese, A.; Bell, A.I.; Bornkamm, G.W.; Mautner, J.; Rickinson, A.B.; Rowe, M. An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog. 2009, 5, e1000341, doi:10.1371/journal.ppat.1000341.
Decaussin, G.; Leclerc, V.; Ooka, T. The lytic cycle of Epstein-Barr virus in the nonproducer Raji line can be rescued by the expression of a 135-kilodalton protein encoded by the BALF2 open reading frame. J. Virol. 1995, 69, 7309–7314.
[40]
Jenson, H.B.; Rabson, M.S.; Miller, G. Palindromic structure and polypeptide expression of 36 kilobase pairs of heterogeneous Epstein-Barr virus (P3HR-1) DNA. J. Virol. 1986, 58, 475–486.
[41]
Rooney, C.; Taylor, N.; Countryman, J.; Jenson, H.; Kolman, J.; Miller, G. Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency. Proc. Natl. Acad. Sci. USA 1988, 85, 9801–9805, doi:10.1073/pnas.85.24.9801.
[42]
Patton, D.F.; Shirley, P.; Raab-Traub, N.; Resnick, L.; Sixbey, J.W. Defective viral DNA in Epstein-Barr virus-associated oral hairy leukoplakia. J. Virol. 1990, 64, 397–400.
[43]
Gan, Y.J.; Razzouk, B.I.; Su, T.; Sixbey, J.W. A defective, rearranged Epstein-Barr virus genome in EBER-negative and EBER-positive Hodgkin's disease. Am. J. Pathol. 2002, 160, 781–786, doi:10.1016/S0002-9440(10)64900-0.
[44]
Ryan, J.L.; Jones, R.J.; Elmore, S.H.; Kenney, S.C.; Miller, G.; Schroeder, J.C.; Gulley, M.L. Epstein-Barr virus WZhet DNA can induce lytic replication in epithelial cells in vitro, although WZhet is not detectable in many human tissues in vivo. Intervirology 2009, 52, 8–16, doi:10.1159/000210833.
[45]
Mainou, B.A.; Raab-Traub, N. LMP1 strain variants: biological and molecular properties. J. Virol. 2006, 80, 6458–6468, doi:10.1128/JVI.00135-06.
[46]
Miller, W.E.; Edwards, R.H.; Walling, D.M.; Raab-Traub, N. Sequence variation in the Epstein-Barr virus latent membrane protein 1. J. Gen. Virol. 1994, 75 (Pt 10), 2729–2740.
[47]
Walling, D.M.; Etienne, W.; Ray, A.J.; Flaitz, C.M.; Nichols, C.M. Persistence and transition of Epstein-Barr virus genotypes in the pathogenesis of oral hairy leukoplakia. J. Infect. Dis. 2004, 190, 387–395.
[48]
Sung, N.S.; Edwards, R.H.; Seillier-Moiseiwitsch, F.; Perkins, A.G.; Zeng, Y.; Raab-Traub, N. Epstein-Barr virus strain variation in nasopharyngeal carcinoma from the endemic and non-endemic regions of China. Int. J. Cancer 1998, 76, 207–215, doi:10.1002/(SICI)1097-0215(19980413)76:2<207::AID-IJC7>3.0.CO;2-0.
[49]
Kanai, K.; Satoh, Y.; Saiki, Y.; Ohtani, H.; Sairenji, T. Difference of Epstein-Barr virus isolates from Japanese patients and African Burkitt's lymphoma cell lines based on the sequence of latent membrane protein 1. Virus Genes 2007, 34, 55–61, doi:10.1007/s11262-006-0010-y.
[50]
Nagamine, M.; Takahara, M.; Kishibe, K.; Nagato, T.; Ishii, H.; Bandoh, N.; Ogino, T.; Harabuchi, Y. Sequence variations of Epstein-Barr virus LMP1 gene in nasal NK/T-cell lymphoma. Virus Genes 2007, 34, 47–54, doi:10.1007/s11262-006-0008-5.
[51]
Lin, S.X.; Zong, Y.S.; Zhang, M.; Han, A.J.; Zhong, B.L.; Liang, Y.J. Study of sequence variations of Epstein-Barr virus LMP1 gene in nasopharyngeal carcinoma. Zhonghua Bing Li Xue Za Zhi 2005, 34, 791–795.
[52]
Zhao, S.; Liu, W.P.; Wang, X.L.; Zhang, W.Y.; Jiang, W.; Tang, Y.; Li, G.D. Detection of the 30 base pair deletion of Epstein-Barr virus latent membrane protein 1 in extranodal nasal type NK/T-cell lymphoma and its prognostic significance. Zhonghua Bing Li Xue Za Zhi 2005, 34, 720–723.
[53]
Shibata, Y.; Hoshino, Y.; Hara, S.; Yagasaki, H.; Kojima, S.; Nishiyama, Y.; Morishima, T.; Kimura, H. Clonality analysis by sequence variation of the latent membrane protein 1 gene in patients with chronic active Epstein-Barr virus infection. J. Med. Virol. 2006, 78, 770–779, doi:10.1002/jmv.20622.
[54]
Saechan, V.; Mori, A.; Mitarnun, W.; Settheetham-Ishida, W.; Ishida, T. Analysis of LMP1 variants of EBV in Southern Thailand: evidence for strain-associated T-cell tropism and pathogenicity. J. Clin. Virol. 2006, 36, 119–125.
[55]
Dardari, R.; Khyatti, M.; Cordeiro, P.; Odda, M.; ElGueddari, B.; Hassar, M.; Menezes, J. High frequency of latent membrane protein-1 30-bp deletion variant with specific single mutations in Epstein-Barr virus-associated nasopharyngeal carcinoma in Moroccan patients. Int. J. Cancer 2006, 118, 1977–1983, doi:10.1002/ijc.21595.
[56]
Li, D.J.; Bei, J.X.; Mai, S.J.; Xu, J.F.; Chen, L.Z.; Zhang, R.H.; Yu, X.J.; Hong, M.H.; Zeng, Y.X.; Kang, T. The dominance of China 1 in the spectrum of Epstein-Barr virus strains from Cantonese patients with nasopharyngeal carcinoma. J. Med. Virol. 2009, 81, 1253–1260.
[57]
Saechan, V.; Settheetham-Ishida, W.; Kimura, R.; Tiwawech, D.; Mitarnun, W.; Ishida, T. Epstein-Barr virus strains defined by the latent membrane protein 1 sequence characterize Thai ethnic groups. J. Gen. Virol. 2010, 91, 2054–2061, doi:10.1099/vir.0.021105-0.
[58]
Nguyen-Van, D.; Ernberg, I.; Phan-Thi Phi, P.; Tran-Thi, C.; Hu, L. Epstein-Barr virus genetic variation in Vietnamese patients with nasopharyngeal carcinoma: full-length analysis of LMP1. Virus Genes 2008, 37, 273–281, doi:10.1007/s11262-008-0262-9.
[59]
Pavlish, O.A.; Diduk, S.V.; Smirnova, K.V.; Shcherbak, L.N.; Goncharova, E.V.; Shalginskikh, N.A.; Arkhipov, V.V.; Kichigina, M.; Stepina, V.N.; Belousova, N.V.; et al. [Mutations of the Epstein-Barr virus LMP1 gene mutations in Russian patients with lymphoid pathology and healthy individuals]. Vopr. Virusol. 2008, 53, 10–16.
[60]
Wang, Y.; Kanai, K.; Satoh, Y.; Luo, B.; Sairenji, T. Carboxyl-terminal sequence variation of latent membrane protein 1 gene in Epstein-Barr virus-associated gastric carcinomas from Eastern China and Japan. Intervirology 2007, 50, 229–236, doi:10.1159/000100566.
[61]
Zuercher, E.; Butticaz, C.; Wyniger, J.; Martinez, R.; Battegay, M.; Boffi El Amari, E.; Dang, T.; Egger, J.F.; Fehr, J.; Mueller-Garamvogyi, E.; et al. Genetic diversity of EBV-encoded LMP1 in the Swiss HIV Cohort Study and implication for NF-Kappab activation. PLoS One 2012, 7, e32168.
[62]
Edwards, R.H.; Sitki-Green, D.; Moore, D.T.; Raab-Traub, N. Potential selection of LMP1 variants in nasopharyngeal carcinoma. J. Virol. 2004, 78, 868–881, doi:10.1128/JVI.78.2.868-881.2004.
[63]
Tierney, R.J.; Edwards, R.H.; Sitki-Green, D.; Croom-Carter, D.; Roy, S.; Yao, Q.Y.; Raab-Traub, N.; Rickinson, A.B. Multiple Epstein-Barr virus strains in patients with infectious mononucleosis: comparison of ex vivo samples with in vitro isolates by use of heteroduplex tracking assays. J. Infect. Dis. 2006, 193, 287–297, doi:10.1086/498913.
[64]
Fafi-Kremer, S.; Morand, P.; Germi, R.; Ballout, M.; Brion, J.P.; Genoulaz, O.; Nicod, S.; Stahl, J.P.; Ruigrok, R.W.; Seigneurin, J.M. A prospective follow-up of Epstein-Barr virus LMP1 genotypes in saliva and blood during infectious mononucleosis. J. Infect. Dis. 2005, 192, 2108–2111, doi:10.1086/498215.
[65]
Rey, J.; Xerri, L.; Bouabdallah, R.; Keuppens, M.; Brousset, P.; Meggetto, F. Detection of different clonal EBV strains in Hodgkin lymphoma and nasopharyngeal carcinoma tissues from the same patient. Br. J. Haematol. 2008, 142, 79–81, doi:10.1111/j.1365-2141.2008.07162.x.
[66]
Palefsky, J.M.; Berline, J.; Greenspan, D.; Greenspan, J.S. Evidence for trafficking of Epstein-Barr virus strains between hairy leukoplakia and peripheral blood lymphocytes. J. Gen. Virol. 2002, 83, 317–321.
Sitki-Green, D.; Covington, M.; Raab-Traub, N. Compartmentalization and transmission of multiple epstein-barr virus strains in asymptomatic carriers. J. Virol. 2003, 77, 1840–1847, doi:10.1128/JVI.77.3.1840-1847.2003.
[69]
Sitki-Green, D.; Edwards, R.H.; Webster-Cyriaque, J.; Raab-Traub, N. Identification of Epstein-Barr virus strain variants in hairy leukoplakia and peripheral blood by use of a heteroduplex tracking assay. J. Virol. 2002, 76, 9645–9656, doi:10.1128/JVI.76.19.9645-9656.2002.
[70]
Sitki-Green, D.L.; Edwards, R.H.; Covington, M.M.; Raab-Traub, N. Biology of Epstein-Barr virus during infectious mononucleosis. J. Infect. Dis. 2004, 189, 483–492, doi:10.1086/380800.
[71]
Hu, L.F.; Zabarovsky, E.R.; Chen, F.; Cao, S.L.; Ernberg, I.; Klein, G.; Winberg, G. Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J. Gen. Virol. 1991, 72 (Pt 10), 2399–2409.
[72]
Hu, L.F.; Chen, F.; Zheng, X.; Ernberg, I.; Cao, S.L.; Christensson, B.; Klein, G.; Winberg, G. Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMP1. Oncogene 1993, 8, 1575–1583.
[73]
Huen, D.S.; Henderson, S.A.; Croom-Carter, D.; Rowe, M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995, 10, 549–560.
[74]
Farrell, P.J. Signal transduction from the Epstein-Barr virus LMP-1 transforming protein. Trends Microbiol. 1998, 6, 175–177. discussion 177-178, doi:10.1016/S0966-842X(98)01262-1.
[75]
Pai, P.C.; Tseng, C.K.; Chuang, C.C.; Wei, K.C.; Hao, S.P.; Hsueh, C.; Chang, K.P.; Tsang, N.M. Polymorphism of C-terminal activation region 2 of Epstein-Barr virus latent membrane protein 1 in predicting distant failure and post-metastatic survival in patients with nasopharyngeal carcinoma. Head Neck 2007, 29, 109–119, doi:10.1002/hed.20483.
[76]
Vaysberg, M.; Hatton, O.; Lambert, S.L.; Snow, A.L.; Wong, B.; Krams, S.M.; Martinez, O.M. Tumor-derived variants of Epstein-Barr virus latent membrane protein 1 induce sustained Erk activation and c-Fos. J. Biol. Chem. 2008, 283, 36573–36585.
[77]
Correa, R.M.; Fellner, M.D.; Alonio, L.V.; Durand, K.; Teyssie, A.R.; Picconi, M.A. Epstein-barr virus (EBV) in healthy carriers: Distribution of genotypes and 30 bp deletion in latent membrane protein-1 (LMP-1) oncogene. J. Med. Virol. 2004, 73, 583–588, doi:10.1002/jmv.20129.
[78]
Cheung, S.T.; Leung, S.F.; Lo, K.W.; Chiu, K.W.; Tam, J.S.; Fok, T.F.; Johnson, P.J.; Lee, J.C.; Huang, D.P. Specific latent membrane protein 1 gene sequences in type 1 and type 2 Epstein-Barr virus from nasopharyngeal carcinoma in Hong Kong. Int. J. Cancer 1998, 76, 399–406, doi:10.1002/(SICI)1097-0215(19980504)76:3<399::AID-IJC18>3.0.CO;2-6.
[79]
Hayashi, K.; Chen, W.G.; Chen, Y.Y.; Murakami, I.; Chen, H.L.; Ohara, N.; Nose, S.; Hamaya, K.; Matsui, S.; Bacchi, M.M.; et al. Deletion of Epstein-Barr virus latent membrane protein 1 gene in Japanese and Brazilian gastric carcinomas, metastatic lesions, and reactive lymphocytes. Am. J. Pathol. 1998, 152, 191–198.
[80]
Zhang, X.S.; Song, K.H.; Mai, H.Q.; Jia, W.H.; Feng, B.J.; Xia, J.C.; Zhang, R.H.; Huang, L.X.; Yu, X.J.; Feng, Q.S.; et al. The 30-bp deletion variant: a polymorphism of latent membrane protein 1 prevalent in endemic and non-endemic areas of nasopharyngeal carcinomas in China. Cancer Lett. 2002, 176, 65–73, doi:10.1016/S0304-3835(01)00733-9.
[81]
Tai, Y.C.; Kim, L.H.; Peh, S.C. High frequency of EBV association and 30-bp deletion in the LMP-1 gene in CD56 lymphomas of the upper aerodigestive tract. Pathol. Int. 2004, 54, 158–166, doi:10.1111/j.1440-1827.2003.01602.x.
[82]
Jen, K.Y.; Higuchi, M.; Cheng, J.; Li, J.; Wu, L.Y.; Li, Y.F.; Lin, H.L.; Chen, Z.; Gurtsevitch, V.; Fujii, M.; et al. Nucleotide sequences and functions of the Epstein-Barr virus latent membrane protein 1 genes isolated from salivary gland lymphoepithelial carcinomas. Virus Genes 2005, 30, 223–235, doi:10.1007/s11262-004-5630-5.
[83]
Chang, K.P.; Hao, S.P.; Lin, S.Y.; Ueng, S.H.; Pai, P.C.; Tseng, C.K.; Hsueh, C.; Hsieh, M.S.; Yu, J.S.; Tsang, N.M. The 30-bp deletion of Epstein-Barr virus latent membrane protein-1 gene has no effect in nasopharyngeal carcinoma. Laryngoscope 2006, 116, 541–546, doi:10.1097/01.mlg.0000201993.53410.40.
[84]
Correa, R.M.; Fellner, M.D.; Durand, K.; Redini, L.; Alonio, V.; Yampolsky, C.; Colobraro, A.; Sevlever, G.; Teyssie, A.; Benetucci, J.; et al. Epstein Barr virus genotypes and LMP-1 variants in HIV-infected patients. J. Med. Virol. 2007, 79, 401–407, doi:10.1002/jmv.20782.
[85]
See, H.S.; Yap, Y.Y.; Yip, W.K.; Seow, H.F. Epstein-Barr virus latent membrane protein-1 (LMP-1) 30-bp deletion and Xho I-loss is associated with type III nasopharyngeal carcinoma in Malaysia. World J. Surg. Oncol. 2008, 6, 18, doi:10.1186/1477-7819-6-18.
[86]
Lorenzetti, M.A.; Gantuz, M.; Altcheh, J.; De Matteo, E.; Chabay, P.A.; Preciado, M.V. Distinctive Epstein-Barr virus variants associated with benign and malignant pediatric pathologies: LMP1 sequence characterization and linkage with other viral gene polymorphisms. J. Clin. Microbiol. 2012, 50, 609–618, doi:10.1128/JCM.05778-11.
[87]
Banko, A.; Lazarevic, I.; Cupic, M.; Stevanovic, G.; Boricic, I.; Jovanovic, T. Carboxy-terminal sequence variation of LMP1 gene in Epstein-Barr-virus-associated mononucleosis and tumors from Serbian patients. J. Med. Virol. 2012, 84, 632–642.
[88]
Hadhri-Guiga, B.; Khabir, A.M.; Mokdad-Gargouri, R.; Ghorbel, A.M.; Drira, M.; Daoud, J.; Frikha, M.; Jlidi, R.; Gargouri, A. Various 30 and 69 bp deletion variants of the Epstein-Barr virus LMP1 may arise by homologous recombination in nasopharyngeal carcinoma of Tunisian patients. Virus Res. 2006, 115, 24–30, doi:10.1016/j.virusres.2005.07.002.
[89]
Larcher, C.; Bernhard, D.; Schaadt, E.; Adler, B.; Ausserlechner, M.J.; Mitterer, M.; Huemer, H.P. Functional analysis of the mutated Epstein-Barr virus oncoprotein LMP1(69del): implications for a new role of naturally occurring LMP1 variants. Haematologica 2003, 88, 1324–1335.
[90]
Chen, J.N.; Ding, Y.G.; Feng, Z.Y.; Li, H.G.; He, D.; Du, H.; Wu, B.; Shao, C.K. Association of distinctive Epstein-Barr virus variants with gastric carcinoma in Guangzhou, southern China. J. Med. Virol. 2010, 82, 658–667, doi:10.1002/jmv.21731.
[91]
Chen, J.N.; Jiang, Y.; Li, H.G.; Ding, Y.G.; Fan, X.J.; Xiao, L.; Han, J.; Du, H.; Shao, C.K. Epstein-Barr virus genome polymorphisms of Epstein-Barr virus-associated gastric carcinoma in gastric remnant carcinoma in Guangzhou, southern China, an endemic area of nasopharyngeal carcinoma. Virus Res. 2011, 160, 191–199, doi:10.1016/j.virusres.2011.06.011.
[92]
BenAyed-Guerfali, D.; Ayadi, W.; Miladi-Abdennadher, I.; Khabir, A.; Sellami-Boudawara, T.; Gargouri, A.; Mokdad-Gargouri, R. Characteristics of epstein barr virus variants associated with gastric carcinoma in Southern Tunisia. Virol. J. 2011, 8, 500, doi:10.1186/1743-422X-8-500.
[93]
Higa, M.; Kinjo, T.; Kamiyama, K.; Iwamasa, T.; Hamada, T.; Iyama, K. Epstein-Barr virus (EBV) subtype in EBV related oral squamous cell carcinoma in Okinawa, a subtropical island in southern Japan, compared with Kitakyushu and Kumamoto in mainland Japan. J. Clin. Pathol. 2002, 55, 414–423, doi:10.1136/jcp.55.6.414.
[94]
Corvalan, A.; Ding, S.; Koriyama, C.; Carrascal, E.; Carrasquilla, G.; Backhouse, C.; Urzua, L.; Argandona, J.; Palma, M.; Eizuru, Y.; et al. Association of a distinctive strain of Epstein-Barr virus with gastric cancer. Int. J. Cancer 2006, 118, 1736–1742, doi:10.1002/ijc.21530.
[95]
Busson, P.; Edwards, R.H.; Tursz, T.; Raab-Traub, N. Sequence polymorphism in the Epstein-Barr virus latent membrane protein (LMP)-2 gene. J. Gen. Virol. 1995, 76 (Pt 1), 139–145.
[96]
Berger, C.; Rothenberger, S.; Bachmann, E.; McQuain, C.; Nadal, D.; Knecht, H. Sequence polymorphisms between latent membrane proteins LMP1 and LMP2A do not correlate in EBV-associated reactive and malignant lympho-proliferations. Int. J. Cancer 1999, 81, 371–375, doi:10.1002/(SICI)1097-0215(19990505)81:3<371::AID-IJC10>3.0.CO;2-D.
[97]
Tanaka, M.; Kawaguchi, Y.; Yokofujita, J.; Takagi, M.; Eishi, Y.; Hirai, K. Sequence variations of Epstein-Barr virus LMP2A gene in gastric carcinoma in Japan. Virus Genes 1999, 19, 103–111, doi:10.1023/A:1008171006400.
[98]
Wang, X.; Liu, X.; Jia, Y.; Chao, Y.; Xing, X.; Wang, Y.; Luo, B. Widespread sequence variation in the Epstein-Barr virus latent membrane protein 2A gene among northern Chinese isolates. J. Gen. Virol. 2010, 91, 2564–2573, doi:10.1099/vir.0.021881-0.
[99]
Han, J.; Chen, J.N.; Zhang, Z.G.; Li, H.G.; Ding, Y.G.; Du, H.; Shao, C.K. Sequence variations of latent membrane protein 2A in Epstein-Barr virus-associated gastric carcinomas from Guangzhou, southern China. PLoS One 2012, 7, e34276.
[100]
Lee, S.P.; Thomas, W.A.; Murray, R.J.; Khanim, F.; Kaur, S.; Young, L.S.; Rowe, M.; Kurilla, M.; Rickinson, A.B. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J. Virol. 1993, 67, 7428–7435.
[101]
Rickinson, A.B.; Moss, D.J. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 1997, 15, 405–431, doi:10.1146/annurev.immunol.15.1.405.
[102]
Khanna, R.; Moss, D.J.; Burrows, S.R. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol. Rev. 1999, 170, 49–64, doi:10.1111/j.1600-065X.1999.tb01328.x.
[103]
Bhatia, K.; Raj, A.; Guitierrez, M.I.; Judde, J.G.; Spangler, G.; Venkatesh, H.; Magrath, I.T. Variation in the sequence of Epstein Barr virus nuclear antigen 1 in normal peripheral blood lymphocytes and in Burkitt's lymphomas. Oncogene 1996, 13, 177–181.
[104]
Habeshaw, G.; Yao, Q.Y.; Bell, A.I.; Morton, D.; Rickinson, A.B. Epstein-Barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt's lymphoma reflect virus strains prevalent in different geographic areas. J. Virol. 1999, 73, 965–975.
[105]
Wrightham, M.N.; Stewart, J.P.; Janjua, N.J.; Pepper, S.D.; Sample, C.; Rooney, C.M.; Arrand, J.R. Antigenic and sequence variation in the C-terminal unique domain of the Epstein-Barr virus nuclear antigen EBNA-1. Virology 1995, 208, 521–530, doi:10.1006/viro.1995.1183.
[106]
Chen, M.R.; Tsai, C.H.; Wu, F.F.; Kan, S.H.; Yang, C.S.; Chen, J.Y. The major immunogenic epitopes of Epstein-Barr virus (EBV) nuclear antigen 1 are encoded by sequence domains which vary among nasopharyngeal carcinoma biopsies and EBV-associated cell lines. J. Gen. Virol. 1999, 80 (Pt 2), 447–455.
[107]
Bell, M.J.; Brennan, R.; Miles, J.J.; Moss, D.J.; Burrows, J.M.; Burrows, S.R. Widespread sequence variation in Epstein-Barr virus nuclear antigen 1 influences the antiviral T cell response. J. Infect. Dis. 2008, 197, 1594–1597, doi:10.1086/587848.
[108]
Ai, J.; Xie, Z.; Liu, C.; Huang, Z.; Xu, J. Analysis of EBNA-1 and LMP-1 variants in diseases associated with EBV infection in Chinese children. Virol. J. 2012, 9, 13, doi:10.1186/1743-422X-9-13.
[109]
Snudden, D.K.; Smith, P.R.; Lai, D.; Ng, M.H.; Griffin, B.E. Alterations in the structure of the EBV nuclear antigen, EBNA1, in epithelial cell tumours. Oncogene 1995, 10, 1545–1552.
[110]
Zhang, X.S.; Wang, H.H.; Hu, L.F.; Li, A.; Zhang, R.H.; Mai, H.Q.; Xia, J.C.; Chen, L.Z.; Zeng, Y.X. V-val subtype of Epstein-Barr virus nuclear antigen 1 preferentially exists in biopsies of nasopharyngeal carcinoma. Cancer Lett. 2004, 211, 11–18, doi:10.1016/j.canlet.2004.01.035.
[111]
Wang, Y.; Liu, X.; Xing, X.; Cui, Y.; Zhao, C.; Luo, B. Variations of Epstein-Barr virus nuclear antigen 1 gene in gastric carcinomas and nasopharyngeal carcinomas from Northern China. Virus Res. 2010, 147, 258–264, doi:10.1016/j.virusres.2009.11.010.
[112]
Do, N.V.; Ingemar, E.; Phi, P.T.; Jenny, A.; Chinh, T.T.; Zeng, Y.; Hu, L. A major EBNA1 variant from Asian EBV isolates shows enhanced transcriptional activity compared to prototype B95.8. Virus Res. 2008, 132, 15–24, doi:10.1016/j.virusres.2007.10.020.
[113]
Mai, S.J.; Xie, D.; Huang, Y.F.; Wang, F.W.; Liao, Y.J.; Deng, H.X.; Liu, W.J.; Hua, W.F.; Zeng, Y.X. The enhanced transcriptional activity of the V-val subtype of Epstein-Barr virus nuclear antigen 1 in epithelial cell lines. Oncol. Rep. 2010, 23, 1417–1424.
[114]
Crawford, D.H.; Macsween, K.F.; Higgins, C.D.; Thomas, R.; McAulay, K.; Williams, H.; Harrison, N.; Reid, S.; Conacher, M.; Douglas, J.; et al. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin. Infect. Dis. 2006, 43, 276–282.
[115]
Lay, M.L.; Lucas, R.M.; Toi, C.; Ratnamohan, M.; Ponsonby, A.L.; Dwyer, D.E. Epstein-Barr Virus Genotypes and Strains in Central Nervous System Demyelinating Disease and Epstein-Barr Virus-Related Illnesses in Australia. Intervirology 2012, 55, 372–379, doi:10.1159/000334693.
[116]
Wang, X.; Wang, Y.; Wu, G.; Chao, Y.; Sun, Z.; Luo, B. Sequence analysis of Epstein-Barr virus EBNA-2 gene coding amino acid 148-487 in nasopharyngeal and gastric carcinomas. Virol. J. 2012, 9, 49, doi:10.1186/1743-422X-9-49.
[117]
Gorzer, I.; Niesters, H.G.; Cornelissen, J.J.; Puchhammer-Stockl, E. Characterization of Epstein-Barr virus Type I variants based on linked polymorphism among EBNA3A, -3B, and -3C genes. Virus. Res. 2006, 118, 105–114, doi:10.1016/j.virusres.2005.11.020.
[118]
Wu, G.; Wang, Y.; Chao, Y.; Jia, Y.; Zhao, C.; Luo, B. Characterization of Epstein-Barr virus type 1 nuclear antigen 3C sequence patterns of nasopharyngeal and gastric carcinomas in northern China. Arch. Virol. 2012, 157, 845–853, doi:10.1007/s00705-012-1241-y.
[119]
Chu, P.G.; Chang, K.L.; Chen, W.G.; Chen, Y.Y.; Shibata, D.; Hayashi, K.; Bacchi, C.; Bacchi, M.; Weiss, L.M. Epstein-Barr virus (EBV) nuclear antigen (EBNA)-4 mutation in EBV-associated malignancies in three different populations. Am. J. Pathol. 1999, 155, 941–947, doi:10.1016/S0002-9440(10)65193-0.
[120]
Arrand, J.R.; Young, L.S.; Tugwood, J.D. Two families of sequences in the small RNA-encoding region of Epstein-Barr virus (EBV) correlate with EBV types A and B. J. Virol. 1989, 63, 983–986.
[121]
Wang, Y.; Zhang, X.; Chao, Y.; Jia, Y.; Xing, X.; Luo, B. New variations of Epstein-Barr virus-encoded small RNA genes in nasopharyngeal carcinomas, gastric carcinomas, and healthy donors in northern China. J. Med. Virol. 2010, 82, 829–836, doi:10.1002/jmv.21714.
[122]
Li, A.; Zhang, X.S.; Jiang, J.H.; Wang, H.H.; Liu, X.Q.; Pan, Z.G.; Zeng, Y.X. Transcriptional expression of RPMS1 in nasopharyngeal carcinoma and its oncogenic potential. Cell Cycle 2005, 4, 304–309.
[123]
Wang, F.W.; Wu, X.R.; Liu, W.J.; Liang, Y.J.; Huang, Y.F.; Liao, Y.J.; Shao, C.K.; Zong, Y.S.; Mai, S.J.; Xie, D. The nucleotide polymorphisms within the Epstein-Barr virus C and Q promoters from nasopharyngeal carcinoma affect transcriptional activity in vitro. Eur. Arch. Otorhinolaryngol. 2012, 269, 931–938, doi:10.1007/s00405-011-1862-x.
[124]
Tierney, R.J.; Kao, K.Y.; Nagra, J.K.; Rickinson, A.B. Epstein-Barr virus BamHI W repeat number limits EBNA2/EBNA-LP coexpression in newly infected B cells and the efficiency of B-cell transformation: a rationale for the multiple W repeats in wild-type virus strains. J. Virol. 2011, 85, 12362–12375.
[125]
Lorenzetti, M.A.; Gutierrez, M.I.; Altcheh, J.; Moscatelli, G.; Moroni, S.; Chabay, P.A.; Preciado, M.V. Epstein-Barr virus BZLF1 gene promoter variants in pediatric patients with acute infectious mononucleosis: its comparison with pediatric lymphomas. J. Med. Virol. 2009, 81, 1912–1917, doi:10.1002/jmv.21616.
[126]
Jin, Y.; Xie, Z.; Lu, G.; Yang, S.; Shen, K. Characterization of variants in the promoter of BZLF1 gene of EBV in nonmalignant EBV-associated diseases in Chinese children. Virol. J. 2010, 7, 92, doi:10.1186/1743-422X-7-92.
[127]
Imajoh, M.; Hashida, Y.; Murakami, M.; Maeda, A.; Sato, T.; Fujieda, M.; Wakiguchi, H.; Daibata, M. Characterization of Epstein-Barr virus (EBV) BZLF1 gene promoter variants and comparison of cellular gene expression profiles in Japanese patients with infectious mononucleosis, chronic active EBV infection, and EBV-associated hemophagocytic lymphohistiocytosis. J. Med. Virol. 2012, 84, 940–946, doi:10.1002/jmv.23299.
[128]
Martini, M.; Capello, D.; Serraino, D.; Navarra, A.; Pierconti, F.; Cenci, T.; Gaidano, G.; Larocca, L.M. Characterization of variants in the promoter of EBV gene BZLF1 in normal donors, HIV-positive patients and in AIDS-related lymphomas. J. Infect. 2007, 54, 298–306, doi:10.1016/j.jinf.2006.04.015.
[129]
Ji, K.M.; Li, C.L.; Meng, G.; Han, A.D.; Wu, X.L. New BZLF1 sequence variations in EBV-associated undifferentiated nasopharyngeal carcinoma in southern China. Arch. Virol. 2008, 153, 1949–1953, doi:10.1007/s00705-008-0195-6.
[130]
Luo, B.; Tang, X.; Jia, Y.; Wang, Y.; Chao, Y.; Zhao, C. Sequence variation of Epstein-Barr virus (EBV) BZLF1 gene in EBV-associated gastric carcinomas and nasopharyngeal carcinomas in Northern China. Microbes Infect. 2011, 13, 776–782, doi:10.1016/j.micinf.2011.04.002.
[131]
Hicks, M.R.; Balesaria, S.; Medina-Palazon, C.; Pandya, M.J.; Woolfson, D.N.; Sinclair, A.J. Biophysical analysis of natural variants of the multimerization region of Epstein-Barr virus lytic-switch protein BZLF1. J. Virol. 2001, 75, 5381–5384, doi:10.1128/JVI.75.11.5381-5384.2001.
[132]
Jia, Y.; Wang, Y.; Chao, Y.; Jing, Y.; Sun, Z.; Luo, B. Sequence analysis of the Epstein-Barr virus (EBV) BRLF1 gene in nasopharyngeal and gastric carcinomas. Virol. J. 2010, 7, 341.
[133]
Jing, Y.Z.; Wang, Y.; Jia, Y.P.; Luo, B. Polymorphisms of Epstein-Barr virus BHRF1 gene, a homologue of bcl-2. Chin. J. Cancer 2010, 29, 1000–1005, doi:10.5732/cjc.010.10241.
[134]
Horst, D.; Burrows, S.R.; Gatherer, D.; van Wilgenburg, B.; Bell, M.J.; Boer, I.G.; Ressing, M.E.; Wiertz, E.J. Epstein-Barr virus isolates retain their capacity to evade T cell immunity through BNLF2a despite extensive sequence variation. J. Virol. 2012, 86, 572–577, doi:10.1128/JVI.05151-11.
[135]
Khanim, F.; Dawson, C.; Meseda, C.A.; Dawson, J.; Mackett, M.; Young, L.S. BHRF1, a viral homologue of the Bcl-2 oncogene, is conserved at both the sequence and functional level in different Epstein-Barr virus isolates. J. Gen. Virol. 1997, 78 (Pt 11), 2987–2999.
Hutajulu, S.H.; Hoebe, E.K.; Verkuijlen, S.A.; Fachiroh, J.; Hariwijanto, B.; Haryana, S.M.; Stevens, S.J.; Greijer, A.E.; Middeldorp, J.M. Conserved mutation of Epstein-Barr virus-encoded BamHI-A Rightward Frame-1 (BARF1) gene in Indonesian nasopharyngeal carcinoma. Infect. Agent Cancer 2010, 5, 16, doi:10.1186/1750-9378-5-16.
[138]
Wang, Y.; Wang, X.F.; Sun, Z.F.; Luo, B. Unique variations of Epstein-Barr virus-encoded BARF1 gene in nasopharyngeal carcinoma biopsies. Virus Res. 2012, 166, 23–30, doi:10.1016/j.virusres.2012.02.022.
[139]
Kawaguchi, A.; Kanai, K.; Satoh, Y.; Touge, C.; Nagata, K.; Sairenji, T.; Inoue, Y. The evolution of Epstein-Barr virus inferred from the conservation and mutation of the virus glycoprotein gp350/220 gene. Virus Genes 2009, 38, 215–223, doi:10.1007/s11262-008-0323-0.
[140]
Luo, B.; Liu, M.; Chao, Y.; Wang, Y.; Jing, Y.; Sun, Z. Characterization of Epstein-Barr virus gp350/220 gene variants in virus isolates from gastric carcinoma and nasopharyngeal carcinoma. Arch. Virol. 2012, 157, 207–216, doi:10.1007/s00705-011-1148-z.
[141]
Cohen, J.I.; Wang, F.; Mannick, J.; Kieff, E. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc. Natl. Acad. Sci. USA 1989, 86, 9558–9562, doi:10.1073/pnas.86.23.9558.
[142]
Sample, J.; Young, L.; Martin, B.; Chatman, T.; Kieff, E.; Rickinson, A. Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J. Virol. 1990, 64, 4084–4092.
[143]
Tomkinson, B.; Kieff, E. Second-site homologous recombination in Epstein-Barr virus: insertion of type 1 EBNA 3 genes in place of type 2 has no effect on in vitro infection. J. Virol. 1992, 66, 780–789.
[144]
Rowe, M.; Young, L.S.; Crocker, J.; Stokes, H.; Henderson, S.; Rickinson, A.B. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J. Exp. Med. 1991, 173, 147–158, doi:10.1084/jem.173.1.147.
[145]
Cohen, J.I.; Picchio, G.R.; Mosier, D.E. Epstein-Barr virus nuclear protein 2 is a critical determinant for tumor growth in SCID mice and for transformation in vitro. J, Virol 1992, 66, 7555–7559.
[146]
Lucchesi, W.; Brady, G.; Dittrich-Breiholz, O.; Kracht, M.; Russ, R.; Farrell, P.J. Differential gene regulation by Epstein-Barr virus type 1 and type 2 EBNA2. J, Virol 2008, 82, 7456–7466, doi:10.1128/JVI.00223-08.
[147]
Cancian, L.; Bosshard, R.; Lucchesi, W.; Karstegl, C.E.; Farrell, P.J. C-terminal region of EBNA-2 determines the superior transforming ability of type 1 Epstein-Barr virus by enhanced gene regulation of LMP-1 and CXCR7. PLoS Pathog. 2011, 7, e1002164, doi:10.1371/journal.ppat.1002164.
